Line 18:
Line 18:
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal adenoma]]
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal adenoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*
**Symptoms related to excess [[glucocorticoid]]
**Symptoms related to excess [[mineralocorticoid]]
|
|
* Round and homogeneous density, smooth contour and sharp margination [15]
* Round and homogeneous density, smooth contour and sharp margination [15]
Line 27:
Line 28:
* Chemical shift evidence of lipid on MRI
* Chemical shift evidence of lipid on MRI
|
|
* [[Cortisol level]]
* Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime
* [[Renin]] (PRA) or plasma renin concentration (PRC): very low in patients with primary aldosteronism, usually less than 1 ng/mL per hour for PRA and usually undetectable for PRC<ref />
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenocortical carcinoma|'''Adrenocortica'''l carcinoma]]
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenocortical carcinoma|'''Adrenocortica'''l carcinoma]]
Line 44:
Line 49:
* Evidence of local invasion or metastases
* Evidence of local invasion or metastases
|
|
* Serum DHEAS
* [[Androgen|Adrenal androgens]] [[[DHEAS]]]
* Measures of clinicallyindicated
* [[Androstenedione]]
* steroid
* Bioavailable [[testosterone]] should be measured in every patient.
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* Serum [[estradiol]] in men and postmenopausal women
* [[Cortisol level]]
* Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime
|-
|-
|'''[[Cushing's syndrome]]'''
|'''[[Cushing's syndrome]]'''
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D [2]
Overview
Adrenal incidentaloma must be differentiated from other diseases that cause adrenal masses such as adrenal adenoma , adrenocortical carcinoma , Cushing's syndrome , pheochromocytoma , and metastasis .
Differentiating Incidentaloma from other Diseases
Differential Diagnosis
Clinical picture
Imagings
Laboratory tests
Adrenal adenoma
Round and homogeneous density, smooth contour and sharp margination [15]
Diameter less than 4 cm, unilateral location
Low unenhanced CT attenuation values (<10 HU) (image 1)
Rapid contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of more than 50 percent)
Isointensity with liver on both T1 and T2 weighted MRI sequences
Chemical shift evidence of lipid on MRI
Cortisol level
Fasting serum cortisol at 8 AM following a 1 mg dose of dexamethasone at bedtime
Renin (PRA) or plasma renin concentration (PRC): very low in patients with primary aldosteronism, usually less than 1 ng/mL per hour for PRA and usually undetectable for PRCThe opening <ref>
tag is malformed or has a bad name
Adrenocortica l carcinoma
Mass effect symptoms; symptoms related to excess glucocorticoid, mineralocorticoid, androgen, or estrogen secretion
Irregular shape
Inhomogeneous density because of central areas of low attenuation due to tumor necrosis (image 4)
Tumor calcification
Diameter usually >4 cm
Unilateral location
High unenhanced CT attenuation values (>20 HU)
Inhomogeneous enhancement on CT with intravenous contrast
Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
Hypointensity compared with liver on T1 weighted MRI and high to intermediate signal intensity on T2 weighted MRI
High standardized uptake value (SUV) on FDG-PET-CT study
Evidence of local invasion or metastases
Cushing's syndrome
Imaging may show adenoma if presents
Pheochromocytoma
Increased attenuation on nonenhanced CT (>20 HU)
Increased mass vascularity (image 2)
Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
High signal intensity on T2 weighted MRI (image 3)
Cystic and hemorrhagic changes
Variable size and may be bilateral
Adrenal metastasis
Symptoms and signs of primary malignancy especially lung cancer.
General constitutional symptoms:
Fever
Fatigue
Weight loss
Irregular shape and inhomogeneous nature
Tendency to be bilateral
High unenhanced CT attenuation values (>20 HU) and enhancement with intravenous contrast on CT
Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
Isointensity or slightly less intense than the liver on T1 weighted MRI and high to intermediate signal intensity on T2 weighted MRI (representing an increased water content)
Elevated standardized uptake value on FDG-PET scan
Differential diagnosis of Cushing's disease from other diseases
The table below summarizes the findings that differentiate Cushing's disease from other conditions that may cause hypertensio n, hyperandrogenism , and obesity . Facial plethora , skin changes , osteoporosis , nephrolithiasis and neuropsychiatric conditions should raise the concern for Cushing's syndrome.[ 1] [ 2] [ 3] [ 4]
Differentiating pheochromocytoma from other diseases
Pheochromocytoma must be differentiated from other causes of paroxysmal hypertension . The differentials include:
Disease
Symptoms
Signs
Investigations
Pheochromocytoma
The symptoms of a pheochromocytoma are those of sympathetic nervous system hyperactivity and include:[1]
Pseudopheochromocytoma (idiopathic)[ 5] [ 6] [ 7] [ 8]
Paroxysmal activation of the sympathetic system causing:
Panic attacks
Laboratory studies that can exclude medical disorders other than panic disorder include:
Labile hypertension (White coat hypertension )
Elevated blood pressure , tachycardia , and may be anxiety in a clinical setting but not in other settings[1]
Hyperthyroidism
Renovascular hypertension
Stroke and compression of lateral medulla (Lateral medullary syndrome )
Difficulty sitting upright without support
Hypotonia of the ipsilateral arm
Ipsilateral decreased pain and temperature sensation in the face
The corneal reflex is usually reduced in the ipsilateral eye
Contralateral loss of pain and thermal sensation involving the body and limbs
Seizures
According to type; it may be focal or generalized, clinical or subclinical:[ 11]
Tonic-clonic seizure :
Repetitive twitches of arm and legs
Tongue bitting
Loss of consciousness
Symptoms occur suddenly and may persist
Muscle tension or tightening that causes twisting of the body, head, arms, or legs
Amnesia
Mood changes (fear, panic, or laughter)
Change in sensation of the skin over the arm, leg, or trunk
Vision changes and light flashes
Hallucinations
Tasting a bitter or metallic flavor
Complex partial seizure :
Confused or dazed and
Not be able to respond to questions or direction
Absence seizure :
Rapid blinking
Few seconds of staring into space
Carcinoid syndrome
Hypertensive crisis occurs with malignant carcinoid syndrome [ 14] . Symptoms include:
Migraine headaches
CT is indicated in patients with:[1] [2]
CT is not indicated in:
Drugs
Sympathomimetic drugs that can induce symptoms simulating pheochromocytoma include:
Baroreflex failure [ 22]
Baroreflex failure patients show a normal or even an increased pressor response to cold-pressor and handgrip testing. These responses are attenuated in patients with autonomic failure.
References
↑ Boscaro M, Barzon L, Fallo F, Sonino N (2001). "Cushing's syndrome". Lancet . 357 (9258): 783–91. doi :10.1016/S0140-6736(00)04172-6 . PMID 11253984 .
↑ Findling JW, Raff H (2001). "Diagnosis and differential diagnosis of Cushing's syndrome". Endocrinol. Metab. Clin. North Am . 30 (3): 729–47. PMID 11571938 .
↑ Newell-Price J, Trainer P, Besser M, Grossman A (1998). "The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states". Endocr. Rev . 19 (5): 647–72. doi :10.1210/edrv.19.5.0346 . PMID 9793762 .
↑ "How Is Metabolic Syndrome Diagnosed? - NHLBI, NIH" .
↑ Mann SJ (1999). "Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment" . Arch Intern Med . 159 (7): 670–4. PMID 10218745 .
↑ Mann SJ (1999). "Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment" . Arch Intern Med . 159 (7): 670–4. PMID 10218745 .
↑ Mann SJ (1996). "Severe paroxysmal hypertension. An automatic syndrome and its relationship to repressed emotions" . Psychosomatics . 37 (5): 444–50. doi :10.1016/S0033-3182(96)71532-3 . PMID 8824124 .
↑ Sharabi Y, Goldstein DS, Bentho O, Saleem A, Pechnik S, Geraci MF; et al. (2007). "Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma" . J Hypertens . 25 (11): 2286–95. doi :10.1097/HJH.0b013e3282ef5fac . PMID 17921824 .
↑ Iglesias P, Acosta M, Sánchez R, Fernández-Reyes MJ, Mon C, Díez JJ (2005). "Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function" . Clin Endocrinol (Oxf) . 63 (1): 66–72. doi :10.1111/j.1365-2265.2005.02301.x . PMID 15963064 .
↑ Mintz G, Pizzarello R, Klein I (1991). "Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment" . J Clin Endocrinol Metab . 73 (1): 146–50. doi :10.1210/jcem-73-1-146 . PMID 2045465 .
↑ 11.0 11.1 Mintz G, Pizzarello R, Klein I (1991). "Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment" . J Clin Endocrinol Metab . 73 (1): 146–50. doi :10.1210/jcem-73-1-146 . PMID 2045465 .
↑ Brigo F, Storti M, Lochner P, Tezzon F, Fiaschi A, Bongiovanni LG; et al. (2012). "Tongue biting in epileptic seizures and psychogenic events: an evidence-based perspective" . Epilepsy Behav . 25 (2): 251–5. doi :10.1016/j.yebeh.2012.06.020 . PMID 23041172 .
↑ Fountain NB, Van Ness PC, Swain-Eng R, Tonn S, Bever CT, American Academy of Neurology Epilepsy Measure Development Panel and the American Medical Association-Convened Physician Consortium for Performance Improvement Independent Measure Development Process (2011). "Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology" . Neurology . 76 (1): 94–9. doi :10.1212/WNL.0b013e318203e9d1 . PMID 21205698 .
↑ Warner RR, Mani S, Profeta J, Grunstein E (1994). "Octreotide treatment of carcinoid hypertensive crisis" . Mt Sinai J Med . 61 (4): 349–55. PMID 7969229 .
↑ Sjöblom SM (1988). "Clinical presentation and prognosis of gastrointestinal carcinoid tumours" . Scand J Gastroenterol . 23 (7): 779–87. PMID 3227292 .
↑ Feldman JM (1986). "Urinary serotonin in the diagnosis of carcinoid tumors" . Clin Chem . 32 (5): 840–4. PMID 2421946 .
↑ Eriksson B, Arnberg H, Oberg K, Hellman U, Lundqvist G, Wernstedt C; et al. (1990). "A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours" . Acta Endocrinol (Copenh) . 122 (2): 145–55. PMID 2316306 .
↑ Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants. European Neuroendocrine Tumor Society (2009). "ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations" . Neuroendocrinology . 90 (2): 167–83. doi :10.1159/000184855 . PMID 19077417 .
↑ Kelman L (2004). "The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs" . Headache . 44 (9): 865–72. doi :10.1111/j.1526-4610.2004.04168.x . PMID 15447695 .
↑ Krentz AJ, Mikhail S, Cantrell P, Hill GM (2001). "Drug Points: Pseudophaeochromocytoma syndrome associated with clozapine" . BMJ . 322 (7296): 1213. PMC 31620 . PMID 11358774 .
↑ Kuchel O (1985). "Pseudopheochromocytoma" . Hypertension . 7 (1): 151–8. PMID 3980057 .
↑ Robertson D, Hollister AS, Biaggioni I, Netterville JL, Mosqueda-Garcia R, Robertson RM (1993). "The diagnosis and treatment of baroreflex failure" . N Engl J Med . 329 (20): 1449–55. doi :10.1056/NEJM199311113292003 . PMID 8413455 .
↑ 23.0 23.1 Zar T, Peixoto AJ (2008). "Paroxysmal hypertension due to baroreflex failure" . Kidney Int . 74 (1): 126–31. doi :10.1038/ki.2008.30 . PMID 18322544 .
Template:WH
Template:WS